Combo drug controls hypertension in hard-to-trea...( A multi-center study of a pill that com...),Health

A multi-center study of a pill that combines two drugs for hypertension shows significant benefit for people with hard-to-control high blood pressure. The study, conducted at the University of Maryland School of Medicine and 118 other sites, was focused on bringing down systolic blood pressure, the top number in a blood pressure reading, which is the more difficult number to bring down. The results of the study, called the INCLUSIVE trial, will be presented at the American Society for Hypertension conference in San Francisco on Tuesday, May 17, 2005.

"The percentage of patients whose blood pressure was controlled in this study was much higher compared to other combination therapy trials," says one of the study's two principal investigators, Elijah Saunders, M.D., professor of medicine at the University of Maryland School of Medicine and a cardiologist and hypertension expert at the University of Maryland Medical Center.

"This was the first large-scale hypertension study to include such a broad range of patient groups," says Dr. Saunders. "We found that this combination therapy reduced systolic blood pressure to a desirable level in 77 percent of the patients, and 83 percent of the patients in our study achieved an acceptable diastolic blood pressure. These results are significant," he adds.

The study began with a total of 1,005 participants with high blood pressure. A broad range of people participated in the study in terms of age and ethnicity. Half of them were women. All were given a diuretic alone for two weeks at the start of the trial. Nearly 30 percent of participants responded to this one drug, so they were eliminated from further participation.

The remaining 736 people were given the combination pill of irbesartan (an angiotensin II receptor blocker) and a diuretic, hydrochlorothiazide, in increasingly stronger doses until their blood pressure reached a desirable goal. At the end of 18 weeks, the participants' systolic b
'"/>

Contact: Bill Seiler
bseiler@umm.edu
410-328-8919
University of Maryland Medical Center
17-May-2005

Page: 1 2 3
Related medicine news :

1. Cost-benefit analysis: Combo treatment costs more, saves money later
2. As heart procedures increase, quality and cost controls are critical
3. Identified: DNA that controls the malaria parasites disguise mechanism
4. Radiation, chemotherapy before surgery controls rectal cancer
5. Gene that controls the severity of asthma identified
6. Diabetes drug controls blood glucose, cardiac risk
7. Scientists identify protein that controls cancer cells
8. Effectiveness of first renin inhibitor drug for treating hypertension is limited
9. Racial disparities in treatment of patients with cirrhosis and complications of portal hypertension
10. Liver stiffness indicates portal hypertension
11. CRP liver protein induces hypertension, UT Southwestern researchers have found